The APC gene was investigated in 31 unrelated polyposis coli families by SSCP analysis and the protein truncation test. Twenty-three germline mutations were identified which gave rise to a variety of different phenotypes. Some of these mutations have already been described; however we report six previously unpublished mutations. Typical disease symptoms were observed in families who harboured mutations between exon 4 (codon 169) and codon 1393 of exon 15. Mutations beyond codon 1403 were associated with more varied phenotype with respect to the development of extracolonic symptoms. In this report we provide support for the notion that there appears to be a correlation between the location of an APC mutation (beyond codon 1403) and extracolonic manifestations of familial adenomatous polyposis. (J Med Genet 1996;33:274-280) 
Familial adenomatous polyposis is probably the best defined colorectal cancer syndrome. It is an autosomal dominantly inherited disease characterised by hundreds to thousands of adenomatous polyps in the colon and rectum with a prevalence of approximately 1 in 10 000. The probability that colorectal cancer will develop in untreated FAP patients approaches 100% by 40 years of age. ' Germline mutations in the adenomatous polyposis coli (APC) gene appear to be the initiating event for the development of this disorder. This gene was localised to 5q21-22 and subsequently cloned.2" It consists of 15 exons, the first 14 of which are relatively short, whereas exon 15 spans over 6-5 kb 3-catenin containing a 20 amino acid consensus sequence between amino acids 1342-2075. By downregulation or redistribution of (-catenin, the APC protein has an important effect on catenin levels within the cell.""'2 Finally, two recent studies1314 examined the subcellular localisation of the APC protein and showed that the wild type APC protein colocalised with cytoplasmic microtubules whereas mutant APC protein did not. The carboxy-terminal region of the APC protein appears to be essential for this association. Thus, the function of the APC protein could be in signal transmission from catenins to the cytoskeleton and, in turn, from the inside of the cell via catenins to the extracellular matrix. '4 There is clinical variability in genetically confirmed FAP patients. The APC phenotype is usually determined using two parameters, the number and age of onset of colorectal polyps and the presence or absence of extracolonic manifestations. Variant forms of FAP have been described and are known as either the attenuated form of APC (AAPC) '5 There are, however, problems with the sensitivity of the technique, as in our hands 33% of our confirmed truncating mutations in exon 15 were not detected using PTT. One explanation that accounts for the failure to detect mutations occurring close to the 5' end of the segments is the small size of the mutated protein product, which may not be as efficiently translated as the expected wild type product. Alternatively, or in addition, the resolving capacity of the acrylamide gel may not be sufficient to detect small protein products as even on a 10-20% gradient gel these predicted synthetic peptides were not observed.
As all mutations detected by PTT were confirmed by SSCP it was possible to calculate the relative percentage of mutations detected using the two methods. From the 18 confirmed mutations in exon 15, 66% were detected by PTT and 94% by SSCP. Therefore, we conclude that SSCP is more sensitive than PIT. As, however, the PTT is rapid and simple we can recommend its application, at least in the first phase of APC mutation screening.
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